Peptide Receptor Radionuclide Therapy (PRRT)

Описание к видео Peptide Receptor Radionuclide Therapy (PRRT)

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Комментарии

Информация по комментариям в разработке

Похожие видео